Q4 2025 Knight Therapeutics Inc Earnings Call Transcript
Key Points
- Knight Therapeutics Inc (KHTRF) reported record revenues of $452 million for 2025, marking a 24% increase from the previous year.
- The company achieved a record adjusted EBITDA of $73 million and record cash flow from operations of $69 million in 2025.
- Knight Therapeutics Inc (KHTRF) successfully launched 10 new products across Canada and Latin America in 2025, with plans for at least 10 more launches in 2026.
- The company expanded its partnerships, adding new products and advancing its pipeline with multiple regulatory submissions and approvals across various territories.
- Knight Therapeutics Inc (KHTRF) improved its financial position, moving from net debt to net cash of $27 million by the end of 2025, and significantly reduced its debt-to-adjusted EBITDA leverage ratio.
- The company faces risks and uncertainties that could cause actual results to differ materially from forward-looking statements.
- Knight Therapeutics Inc (KHTRF) experienced increased operating expenses, with sales, marketing, and R&D expenses rising by 30% in 2025.
- The company recorded a net loss of $6.4 million due to mark-to-market revaluations of strategic fund investments.
- There were declines in mature and branded generics due to lifecycle issues and the termination of a non-strategic distribution agreement in Colombia.
- Knight Therapeutics Inc (KHTRF) anticipates an increase in operating expenses in 2026 due to continued investment in new product launches and brand support.
Good morning, ladies and gentlemen. My name is Sylvie, and I will be your operator today. Welcome to Knight Therapeutics fourth quarter and year-end 2025 results conference call.
Before turning the call over to Samira Sakhia, President and CEO of Knight, listeners are reminded that portions of today's discussion may, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements.
The company considers the assumptions on which these forward looking statements are based to be reasonable at the time they were prepared but cautions that these assumptions regarding the future events, many of which are beyond the control of the company and its subsidiaries may ultimately prove to be incorrect.
The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, except as required by law. We would also like to remind you questions during today's call will be taken from analysts only.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
